Predictive Oncology (Nasdaq: POAI) reported financial and operating results for Q3 2025.
The company initiated a digital asset treasury strategy focused on the ATH token of the Aethir network.
Key highlights included significant cash gross proceeds and in-kind contributions totaling millions of dollars.
Predictive Oncology appointed Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, to its Board of Directors.
Digital Asset Strategy Expansion
Introduced a new business line in active digital asset management through investments in the ATH token.
Strategic Compute Reserve
Utilizing ATH on the Aethir network to potentially create utility for digital assets and meet AI infrastructure demand.
Partnership with Every Cure
Collaboration to repurpose drugs for new indications, aiming to improve patient outcomes.
Financial Status
Reported cash and cash equivalents of $181,667 and a stockholders' deficit of $77.4 million at the end of Q3 2025.
- The digital asset strategy marks a significant shift towards active digital asset management for Predictive Oncology.
- Partnerships and collaborations demonstrate the company's commitment to innovation and improving patient outcomes through drug repurposing.
- Financial results reflect the investments and initiatives undertaken by Predictive Oncology in the third quarter of 2025.
The third quarter of 2025 showcased Predictive Oncology's strategic moves towards digital asset management and innovative collaborations in the healthcare industry.